ISRG Sales Jump 22%: Can Growth Stay Ahead of Procedure Volumes?

Zacks
Zacks에서 열기
ISRG Sales Jump 22%: Can Growth Stay Ahead of Procedure Volumes?

Intuitive Surgical’s ISRG third-quarter 2026 revenues increased 22% year over year to just over $3 billion, outpacing 15% growth in total da Vinci and Ion procedures. Sales growth substantially exceeding procedure growth underscores the company’s ability to capitalize on its expanding installed base, increased system placements and growing adoption of newer technologies. Recurring revenues accounted for 84% of total sales, highlighting the importance of instruments and accessories (I&A), system servicing and the broader installed-base ecosystem to revenue generation.

System placements were a major sales driver during the third quarter. Da Vinci placements increased 28% to 546 systems. Net da Vinci placements rose 40%, expanding the installed base significantly. Systems revenues grew 30% to $769 million, and service revenues increased 22% to $482 million.

Meanwhile, I&A revenues advanced 18% to $1.8 billion. The richer mix of da Vinci 5, single-port (SP) systems and Ion, along with higher integration and upgrade volumes, supported revenue growth beyond underlying procedure expansion. Higher SP utilization and da Vinci 5-specific instruments also lifted I&A revenue per procedure to approximately $1,860 from $1,800 a year earlier.

However, sustaining this gap may become more challenging as pricing initiatives take effect. Intuitive Surgical expects planned instrument pricing changes and China’s policy-driven price reductions to lower da Vinci I&A revenue per procedure by approximately 3% to 5% on a mix-constant basis, once fully implemented. The impact will build progressively through 2027.

Higher SP penetration, da Vinci 5 adoption, Force Feedback instruments and additional technology could partially offset the pressure. Management also expects cost-reduction programs to help absorb the modest gross-margin impact. Revenue growth may continue to outpace procedure growth, supported by expanding system placements, a favorable product mix and innovation-driven monetization despite pricing pressures.

Peer Updates

Boston Scientific’s BSX third-quarter 2026 organic sales grew 1.5% year over year to $5.14 billion, with growth constrained by a cybersecurity incident that reduced sales growth by approximately 300 basis points, as per management estimates. Growth was supported by Neuromodulation (up 13%), including strong demand for Nalu peripheral nerve stimulation technology.

Interventional Cardiology sales increased 19%, driven by imaging and drug-eluting technologies. AGENT drug-coated balloons also continued gaining traction. However, EP sales fell 5% amid competition, while WATCHMAN declined 6%. Although sales are likely to continue its growth at current pace, cyber-related order normalization, EP competition and China pricing pressure could weigh on the metric.

GE HealthCare Technologies’ GEHC third-quarter 2026 revenues increased 6.2% organically to approximately $5.5 billion, with growth across all segments. Product revenues rose 6.7%, while service revenues grew 8.1%, demonstrating strength in both equipment and services. Advanced Imaging Solutions benefited from CT, cardiovascular interventional solutions and surgical innovations, while Pharmaceutical Diagnostics grew 13.8% on demand for contrast media and radiopharmaceuticals.

New products, including AI-enabled imaging platforms and Flyrcado, supported demand, along with contributions from strategic pricing and premium product positioning. Strong demand across all segments is expected to support sales growth going forward. However, rising memory-chip prices, higher oil costs and pricing pressures could weigh on growth and profitability.

ISRG’s Price Performance, Valuation and Estimates

Shares of ISRG have lost 21.6% so far this year compared with a 0.9% decline of the industry.

Zacks Investment Research
Image Source: Zacks Investment Research

From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 36.53, above the industry average. But, it is significantly lower than its five-year median of 66.94. ISRG carries a Value Score of D.

Zacks Investment Research
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 25.9% rise from the year-ago period’s level.

Zacks Investment Research
Image Source: Zacks Investment Research

The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
 
Boston Scientific Corporation (BSX): Free Stock Analysis Report
 
GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research